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Abstract 
Background: In pregnancy, reduction of HIV plasma viral load (pVL) for the prevention of vertical transmission is 
time-constrained. The study primary objective is to investigate factors associated with faster initial HIV RNA half-life 
decay when combination antiretroviral treatment (cART) is initiated in pregnancy.
Methods: This was a multicentre, retrospective, observational study, conducted in south England, United Kingdom, 
between August 2001 and February 2018. Data were extracted from case notes of eligible women initiating cART dur-
ing the index pregnancy. Anonymised data were collated and analysed centrally. Regression analyses were conducted 
to determine factors associated with faster HIV RNA half-life decay in the first 14 days after commencing cART (first-
phase), and with achieving an undetectable maternal pVL by 36 weeks’ gestation. We then assessed whether HIV- and 
obstetric- related parameters differed by antiretroviral third agent class and whether the proportions of women with 
undetectable pVL at 36 weeks’ gestation and at delivery differed by antiretroviral third agent class.
Results: Baseline pVL was the only independent factor associated with faster first-phase HIV RNA half-life decay on 
commencing cART. Lower pVL on day 14 after starting cART was associated with an increased likelihood of achieving 
an undetectable pVL by 36 weeks’ gestation. Integrase inhibitor-based cART was associated with a faster first-phase 
HIV RNA half-life decay on commencing cART. Overall, 73% and 85% of women had an undetectable pVL at 36 weeks’ 
gestation and at delivery respectively, with no significant difference by antiretroviral third agent class.
Conclusions: Only high baseline pVL independently contributed to a faster rate of first-phase viral half-life decay. pVL 
at 14 days after initiating cART allows early identification of treatment failure. In the first 14 days after initiating cART in 
pregnancy, integrase inhibitor-based cART reduced maternal pVL faster than protease inhibitor- and non-nucleoside 
reverse transcriptase-based cART. While our study findings support INSTI use when initiated in pregnancy especially 
when initiated at later gestations and in those with higher baseline pVL, other non-INSTI based cART with more data 
on safety in pregnancy also performed well.
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Background
In the UK, opt-out antenatal HIV-1/2 (hereafter referred 
to as HIV) screening, combination antiretroviral treat-
ment (cART) and infant formula feeding have successfully 
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reduced rates of vertical transmission of HIV from 25% 
in 1993 [1], to the present national rate of < 0.5% [2–4]. In 
recent years, the majority of pregnant women living with 
HIV (WLWH) in the UK conceive on cART and maintain 
HIV suppression throughout pregnancy [4]. However, as 
recently as 2015–2016, 30% of pregnant WLWH in the 
UK were still initiating cART during pregnancy [5].
Guidance regarding the timing of cART initia-
tion and the class of compounds used during preg-
nancy has evolved over the study period and continue 
to vary between guidelines [6–9]. British HIV Asso-
ciation (BHIVA) guidelines recommend that if maternal 
plasma viral load (pVL) is > 100,000 copies/mL and/or 
CD4+ count is < 200 cells/µL, cART should be initiated 
within the first trimester, and that all women should have 
commenced cART by 24  weeks’ gestation [10]. Women 
presenting with untreated HIV beyond 28  weeks’ ges-
tation should initiate cART immediately, and if pVL 
is > 100,000 copies/mL, a three- or four-drug regimen 
including raltegravir or dolutegravir is recommended. 
Read et  al. demonstrated that delaying the initiation of 
cART beyond 26.3  weeks’ gestation when baseline pVL 
is < 10,000 copies/mL, or beyond 20.4  weeks’ gestation 
when baseline pVL is > 100,000 copies/mL, was associ-
ated with a reduced likelihood of achieving pVL < 50 cop-
ies/mL by delivery [11].
The rationale behind recommending the initiation of 
integrase strand transferase inhibitor (INSTI)-based 
cART, especially later in pregnancy, is the presumption 
that a more rapid reduction in maternal pVL will result 
in a higher chance of having an undetectable maternal 
pVL by delivery, with subsequent lower rates of perina-
tal HIV acquisition. Maternal viral burden is a strong 
predictor of perinatal HIV transmission, with a vertical 
transmission risk of 63% when untreated maternal pVL 
is > 100,000 copies/mL during pregnancy and at delivery 
[12], compared to 0.1% when maternal pVL is < 50 cop-
ies/mL on cART [2]. The risk of vertical transmission 
increases with shorter periods on cART prior to deliv-
ery: 3.5% with > 16 weeks of cART and 9% in women who 
initiate cART < 4  weeks prior to delivery [13]. However, 
the reductions in HIV vertical transmission are only 
partly explained by reductions in maternal pVL: firstly, 
in ACTG 076, maternal pVL at delivery in women initiat-
ing zidovudine monotherapy during pregnancy was only 
0.24  log10 HIV RNA copies/mL lower than in the placebo 
group, but HIV vertical transmission reduced by 67% in 
the zidovudine group [14, 15]. Secondly, a single-dose of 
nevirapine administered at the onset of labour was capa-
ble of reducing HIV vertical transmission by nearly 50% 
[16] compared to zidovudine monotherapy initiated dur-
ing labour. Given these findings, the reduction in vertical 
transmission in WLWH on cART during pregnancy can 
be considered to be the result of both treatment as pre-
vention and infant peri-exposure prophylaxis.
Observational studies suggest that in the absence of 
cART and in exclusively formula-fed babies, two-thirds 
of HIV vertical transmissions occur during the intra-
partum period [17]. However, in the cART era, 80% of 
HIV vertical transmission is thought to occur during the 
later stages of the antepartum period, prior to the onset 
of labour [18]. For women with untreated HIV infec-
tion, strategies that rapidly suppress maternal pVL during 
pregnancy are desirable, although the evidence that this 
directly translates into fewer HIV vertical transmissions 
is not yet available.
Modelling and clinical studies have demonstrated that 
when three or more antiretroviral drugs are initiated, 
a rapid exponential decline in pVL occurs in the first 
6–14  days [19, 20], followed by a slower, second phase 
exponential decline, before pVL suppression [19, 21]. 
Choice of cART has been shown to affect time to viral 
suppression, notably with INSTI-based regimens achiev-
ing viral suppression significantly faster than other drug 
classes [22, 23].
The primary aim of our study was to investigate the 
factors associated with a faster first-phase plasma HIV 
RNA decay in women initiating cART during pregnancy. 
Secondary aims included investigating factors associated 
with an increased likelihood of having an undetectable 
pVL by 36 weeks’ gestation (given that in the UK, recom-
mendations for mode of delivery are guided by maternal 
pVL at 36 weeks’ gestation [10] and investigating differ-
ences in HIV- and obstetric-related parameters when 
stratified by antiretroviral third agent class.
Methods
Study setting and ethical considerations
We conducted a retrospective case note review of all 
women initiating cART in pregnancy at HIV tertiary cen-
tres in south England, United Kingdom. The overall study 
was conducted between August 2001 and February 2018 
to avoid bias, but the actual start dates varied according 
to site. All data were obtained as part of routine clini-
cal care, anonymised at site, and then collated centrally 
for analysis. As per the National Research Ethics Service 
guidelines [24], additional patient consent and ethical 
approval were not required.
Eligibility criteria
Inclusion criteria were any woman commencing or re-
commencing cART during the index pregnancy with a 
quantifiable pVL at baseline, and further evaluation on 
day 14 (± 3  days) following cART initiation. Subjects 
were excluded if poor adherence to cART was reported 
by either the subject or clinician.
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Data collection
Clinical data collected included baseline demograph-
ics, HIV-specific parameters (cART history, CD4+ T cell 
count and pVL during index pregnancy) and obstetric 
and infant specific information (estimated due date and 
actual delivery date). Aggregate level data on infant HIV 
infection status (where available) was provided by the 
National Surveillance of HIV in Pregnancy and Child-
hood [25].
Outcome measures
The primary outcome was first-phase plasma HIV RNA 
half-life decay rate, 14  days after commencing cART. 
First phase HIV RNA half-life decay (T/2) was calculated 
using the formula: n ×  log10 0.5/log10  (VL1/VLBL), where 
n = number of days to  VL1;  VL1 = plasma HIV RNA load 
measured 14  days following the initiation of cART and 
 VLBL = plasma HIV RNA load measured prior to the 
initiation of cART. T/2 was only calculated where  VL1 
was quantifiable. In a secondary analysis, when  VL1 was 
reported as < 50 or < 20 HIV RNA copies/mL at day 14, 
a value of 49 or 19 HIV RNA copies/mL were imputed 
respectively, to enable an estimation of the slowest first 
phase T/2 in these women. Secondary outcomes were 
time taken to achieve undetectable maternal pVL (lower 
than the limits of quantification) and proportion of 
women with an undetectable pVL by 36 weeks’ gestation 
and by delivery. Subjects who did not achieve an unde-
tectable pVL were censored at delivery.
Statistical analyses
Descriptive statistics summarised variables using median 
(interquartile range) and total (percentage). For the pur-
poses of this study, the impact of the three dual nucleos(t)
ide reverse transcriptase inhibitors (NRTIs) used were 
considered equal. In subjects on quadruple therapy com-
prising dual NRTIs, an INSTI and a protease inhibitor 
(PI), T/2 was presumed to reflect the INSTI component.
Maternal pVL of < 50 copies/mL were regarded as 
undetectable, including those measured between 20 and 
49 copies/mL. All quantifiable pVL ≥ 20 copies/mL were 
included when calculating T/2. Time taken to achieve an 
undetectable pVL was calculated assuming that the date 
an undetectable pVL was achieved was the mid-point 
between the last detectable and first undetectable pVL.
Regression analysis was performed to investigate fac-
tors associated with faster T/2 (linear regression analysis) 
and with having an undetectable pVL at 36  weeks’ ges-
tation (logistic regression analysis). Kruskall-Wallis test 
was used to assess whether HIV- and obstetric- related 
parameters differed by antiretroviral third agent class. 
Mann–Whitney test (with Bonferroni correction) was 
then used to compare the parameters between antiret-
roviral third agent class. Fisher’s exact test was used to 
assess whether the proportions of women with undetect-
able pVL at 36  weeks’ gestation and at delivery differed 
by antiretroviral third agent class. All statistical analy-
ses were conducted using SPSS version 24 (IBM Corp, 
Armonk, NY, US). Statistical significance was defined 
as < 0.05 throughout.
Results
Of the 221 pregnant women at 11 participating HIV cen-
tres who initiated cART during the index pregnancy and 
had sufficient data for analysis, 192 had a detectable pVL 
after 14 days therapy. 29 women had  VL1 < 50 copies/mL 
and are described separately.
Baseline characteristics
Baseline characteristics of the 192 women included in 
the main analysis are described in Table  1. 83.3% were 
Black African/Caribbean, 98.5% identified heterosexual 
intercourse as their route of HIV acquisition, 63.5% were 
cART-naïve and median  CD4+ count prior to initiating 
cART (baseline) was 339 cells/µL (Table 1). 126 (65.6%) 
had pre-cART (baseline) plasma HIV RNA < 30,000 cop-
ies/mL, 37 (19.3%) between 30,000 and 100,000 HIV 
RNA copies/mL and 29 (15.1%) had baseline plasma HIV 
RNA > 100,000 copies/mL. 91% of women commenced 
cART before 28  weeks’ gestation: 181 (94.3%) women 
initiated a dual NRTI backbone plus a third agent, 11 
(5.7%) initiated abacavir, lamivudine and zidovudine 
(ABC/3TC/AZT) (Table  1) and seven (3.6%) initiated 
quadruple cART. Amongst the 192 women included 
in the main analysis, pVL fell by a median of 1.8  log10 
HIV RNA copies/mL 14  days after initiating cART, and 
median T/2 was 2.5 days (Table 1).
Factors associated with first‑phase plasma HIV RNA 
half‑life decay
Univariate linear regression analysis demonstrated that 
lower baseline CD4+ T-cell count, higher  VLBL and 
INSTI-based cART were associated with faster viral 
decay (shorter T/2) (Table 2). However, in multivariable 
regression analysis, only higher  VLBL remained inde-
pendently associated with shorter T/2 (− 0.61 days per 1 
 log10 plasma HIV RNA higher, p < 0.001) (Table 2).
Factors associated with having an undetectable maternal 
plasma viral load at 36 weeks’ gestation
In multivariate logistic regression analysis, the following 
factors were associated with a higher probability of hav-
ing an undetectable maternal pVL by 36 weeks’ gestation: 
lower maternal pVL 14 days after initiating cART (odds 
ratio (OR) 0.05, 95% confidence interval (CI) 0.01, 0.19) 
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and earlier gestational age when cART was initiated (OR 
0.66, 95% CI 0.58, 0.76) (Table 3).
Differences in HIV‑ and obstetric‑related parameters 
when stratified according to antiretroviral third agent class
T/2 was significantly shorter in women commenced 
on INSTIs compared to those commenced on PIs, 
non-nucleoside reverse transcriptase inhibitor (NNRTIs), 
and ABC/3TC/AZT (p < 0.001, p < 0.001 and p = 0.03, 
respectively) (Table  4). T/2 was significantly longer 
in women commenced on PIs compared to NNRTIs, 
p = 0.03 (Table 4).
Women who initiated an INSTI had significantly 
higher  VLBL compared to women initiating PIs and 
Table 1 Baseline characteristics, cART regimens and responses of the women who commenced cART during pregnancy
Baseline characteristics, antiretroviral treatment regimens and responses of the 221 women living with HIV, who commenced combination antiretroviral therapy 
during index pregnancy
IQR interquartile range, cART combination antiretroviral treatment, ABC abacavir, 3TC lamivudine, AZT zidovudine, TDF tenofovir disoproxil fumarate, FTC emtricitabine, 
PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor
Values are median (IQR) or total (%) Women initiating cART during index 
pregnancy and with a quantifiable HIV RNA 
at day 14
(n = 192)
Women initiating cART during index 
pregnancy and with HIV RNA below the limits 
of quantification at day 14
(n = 29)
Age (years) 31.0 (26.5, 34.0) 31.0 (25.5, 36.0)
Black African and/or Caribbean ethnicity 160 (83.3) 26 (89.7)
HIV acquired via heterosexual intercourse 189 (98.5) 28 (96.6)
Hepatitis B and/or C co-infection 2 (1.0) 4 (13.7)
Received cART previously 70 (36.5) 9 (31.0)
Gestational age when cART initiated, weeks 20.8 (16.9, 24.4) 21.9 (19.0, 24.3)
Baseline  CD4+ T-cell count, cells/µL 339 (212, 481) 520 (334–637)
Baseline plasma HIV RNA,  log10 copies/mL 4.2 (3.8, 4.7) 3.1 (2.9–3.6)
Plasma HIV RNA 14 days after initiating cART, 
 log10 copies/mL
2.4 (2.1, 2.9) All < 1.7
First-phase HIV RNA half-life decay, days 2.5 (2.1, 3.0) 2.9 (2.2, 3.6)
Women with pVL < 50 copies/mL at 36 weeks’ 
gestation
139 (72.4) 29 (100)
Women with pVL < 50 copies/mL at delivery 163 (84.9) 29 (100)
Gestational age at delivery, weeks 39.1 (38.0, 40.4) 39.0 (38.0, 40.0)
cART regimen used
 ABC/3TC/AZT 11 (5.7) 3 (10.3)
 Dual NRTI backbone 181 (94.3) 26 (89.7)
  AZT + 3TC 75 (39.1) 11 (37.9)
  ABC + 3TC 41 (21.4) 6 (20.7)
  TDF + FTC 65 (33.9) 9 (31.0)
 Dual NRTI backbone + PI 132 (68.8) 20 (69.0)
  Atazanavir/ritonavir 60 (31.1) 9 (31.0)
  Darunavir/ritonavir 11 (5.7) 1 (3.4)
  Lopinavir/ritonavir 50 (26.0) 3 (10.3)
  Saquinavir/ritonavir 11 (5.7) 7 (24.1)
 Dual NRTI backbone + NNRTI 32 (16.7) 2 (6.9)
  Nevirapine 26 (13.5) 2 (6.9)
  Efavirenz 5 (2.6) 0
  Rilpivirine 1 (0.5) 0
 Dual NRTI backbone + INSTI 17 (8.9) 4 (13.8)
  Raltegravir 11 (5.7) 1 (3.4)
  Dolutegravir 6 (3.1) 3 (10.3)
Infant HIV status at birth
 HIV negative 150 (78.1) 21 (72.4)
 Data not available 42 (21.9) 8 (27.6)
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ABC/3TC/AZT (p < 0.001 and p < 0.001, respectively), 
while women commenced on ABC/3TC/AZT had sig-
nificantly lower  VLBL and higher baseline CD4 + counts 
compared to women commenced on PIs and NNRTIs 
(Table  4). Women who initiated NNRTIs had lower 
baseline CD4 compared to women initiated on PIs. 
While there was no statistically significant difference 
in the gestational age at which cART was commenced 
when stratified according to the three-third agent 
antiretroviral classes and ABC/3TC/AZT (Table  4), 
higher  VLBL was significantly associated with earlier 
gestational age when cART was initiated, p = 0.02.
Between the four groups, the overall time to an unde-
tectable pVL was numerically shorter in women com-
menced on INSTIs, but statistically only approached 
significance when comparing women initiating INSTIs 
(27.5 days) and NNRTIs (51.5 days), p = 0.05 (Table 4).
An undetectable pVL was seen in 72.9% of all women 
by 36  weeks gestational age with broadly similar rates 
across the three antiretroviral third agent classes: PIs 
72.0%, NNRTIs 65.6% and INSTIs 76.5% (Table  4). 164 
(85.4%) women had an undetectable pVL by delivery: PIs 
85.6%, NNRTIs 75.0% and INSTIs 94.1% (Table  4). All 
women who initiated ABC/3TC/AZT had undetectable 
pVL at both 36  weeks’ gestation and delivery. Statisti-
cally, the proportions of women with undetectable pVL 
at 36 weeks’ gestation and at delivery did not differ sig-
nificantly by antiretroviral third agent class (p = 0.13 and 
p = 0.17, respectively).
Women with pVL < 50 copies/mL at day 14 following cART 
initiation
Baseline characteristics for the 29 women with  VL1 < 50 
copies/mL were broadly similar to the 192 women 
included in the main analysis (Table  1). However, this 
cohort of 29 women had significantly higher baseline 
CD4+ count (p = 0.001), lower  VLBL (p < 0.001), a higher 
proportion with Hepatitis B co-infection (p = 0.007), and 
all women had  VLBL < 30,000 copies/mL. The longest esti-
mated T/2 in this cohort of 29 women was similar to the 
T/2 seen in the subgroup of women included in the main 
analysis with  VLBL < 30,000 copies/mL, p = 0.354.
Infant HIV infection rates
Infant HIV infection status was established for 171/221. 
All 171/221 infants were negative by molecular HIV 
testing at birth. For the remaining 50/221, infection 
status was not available. Although data on infant HIV 
peri-exposure prophylaxis were not available, each cen-
tre managed infants according to the contemporaneous 
Table 2 Linear regression analysis investigating factors associated with first-phase HIV RNA half-life decay
CI confidence interval, cART combination antiretroviral treatment, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand 
transferase inhibitor
a Change (95% CI) reflects the associated impact of each independent variable in the model on the first-phase HIV RNA half-life decay
Univariate analysis Multivariate analysis
Change (95% CI)a p‑value Change (95% CI)a p‑value
Maternal age, per 1-year higher 0.02 (− 0.01, 0.05) 0.24
Black African/Caribbean ethnicity − 0.13 (− 0.61, 0.35) 0.17
HIV acquired via heterosexual intercourse 1.08 (− 0.34, 2.51) 0.14
Previous cART use − 0.08 (− 0.45, 0.29) 0.67
Baseline  CD4+ T-cell count, per 10 cells/µL increase 0.01 (0.00, 0.02) 0.003 0.00 (− 0.01, 0.01) 0.47
Baseline plasma HIV RNA, per 1  log10 copies/mL higher − 0.71 (− 0.97, − 0.46) < 0.001 − 0.611 (− 0.918, − 0.305) < 0.001
Gestational age when cART was started, per 1-week higher − 0.02 (− 0.05, 0.01) 0.21
Antiretroviral third agent class
 PI 0.34 (− 0.04, 0.72) 0.08
 NNRTI − 0.27 (− 0.74, 0.21) 0.27
 INSTI − 0.84 (− 1.46, − 0.23) 0.007 − 0.365 (− 0.982, 0.251) 0.24
Table 3 Logistic regression investigating factors 
associated with  having an  undetectable maternal pVL 
by 36 weeks’ gestation
Multivariate logistic regression analysis investigating factors associated with 
having an undetectable maternal plasma viral load by 36 weeks’ gestation
CI confidence interval, cART combination antiretroviral treatment, pVL plasma 
viral load
Odds ratio (95% CI)
Maternal age, years 0.99 (0.90, 1.08)
Baseline  CD4+ T-cell count, cells/µL 1.00 (0.99, 1.05)
Baseline plasma HIV RNA,  log10 copies/mL 0.88 (0.28, 2.81)
Plasma HIV RNA 14 days after initiating cART,  log10 
copies/mL
0.05 (0.01, 0.19)
Gestational age when cART was started, weeks 0.66 (0.58, 0.76)
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version of the BHIVA guidelines on the management of 
HIV infection in pregnancy.
Discussion
In this study, higher baseline plasma viral load  (VLBL) was 
the sole independent predictor of faster first-phase HIV 
RNA decay. Secondly, lower maternal pVL 14 days after 
cART initiation and earlier gestational age when cART 
was initiated independently predicted a higher likelihood 
of having an undetectable maternal pVL at 36  weeks’ 
gestation.
Overall, women in this cohort experienced a median 
1.8  log10 copies/mL decline in pVL 14 days after initiating 
cART, with the shortest T/2 and thus, largest HIV RNA 
decline seen in women on INSTIs (despite small numbers 
of women on INSTIs), in keeping with the DolPHIN-1 
(Dolutegravir in pregnant HIV mothers and their neo-
nates) [26] study results demonstrating superior virologi-
cal responses with dolutegravir-based cART compared to 
efavirenz-based cART when initiated in late pregnancy 
in low and middle-income settings. This strengthens the 
recommendation for assessing response to cART at this 
early stage and emphasises that clinicians and patients 
should expect around a 99% reduction in maternal pVL 
after 2 weeks of cART. Less convincing reductions in pVL 
at day 14, regardless of third agent in the cART regime, 
should be a cause for concern. Current BHIVA guidelines 
recommending all women should have started cART by 
Table 4 HIV- and obstetric-related parameters, stratified according to antiretroviral third agent class
PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor, ABC abacavir, 3TC lamivudine, AZT zidovudine, 
cART combination antiretroviral treatment, pVL plasma viral load









p‑values (with Bonferroni correction)
HIV RNA half-life decay, days 2.6 (1.6–11.5) 2.3 (1.4–5.3) 1.8 (1.1–6.0) 2.6 (1.8–10.3) χ2(3) = 30.92, p < 0.001
PI vs NNRTI, p = 0.03
PI vs INSTI, p < 0.001
PI vs ABC/3TC/AZT, p = 0.87
NNRTI vs INSTI, p < 0.001
NNRTI vs ABC/3TC/AZT, p = 0.32
INSTI vs ABC/3TC/AZT, p = 0.03
Baseline pVL,  log10 copies/mL 4.2 (2.5–5.8) 4.3 (2.8–5.4) 5.0 (4.0–5.8) 3.8 (2.9–4.5) χ
2(3) = 28.14, p < 0.001
PI vs NNRTI, p = 0.13
PI vs INSTI, p < 0.001
PI vs ABC/3TC/AZT, p = 0.04
NNRTI vs INSTI, p = 0.18
NNRTI vs ABC/3TC/AZT, p = 0.03
INSTI vs ABC/3TC/AZT, p < 0.001
Baseline  CD4+ T-cell count, cells/µL 359 (63–1136) 207 (30–848) 215 (10–700) 574 (290–1008) χ2(3) = 31.20, p < 0.001
PI vs NNRTI, p < 0.001
PI vs INSTI, p = 0.28
PI vs ABC/3TC/AZT, p = 0.03
NNRTI vs INSTI, p = 0.56
NNRTI vs ABC/3TC/AZT, p < 0.001
INSTI vs ABC/3TC/AZT, p = 0.06
Gestational age when cART was started, 
weeks
21.2 (5.7–39.6) 18.9 (4.9–34.0) 17.6 (8.1–34.4) 21.9 (10.9–24.0) χ2(3) = 3.67, p = 0.299
pVL 14 days after cART was initiated,  log10 
HIV RNA copies/mL
2.5 (1.5–4.1) 2.5 (1.8–3.6) 2.4 (1.5–4.3) 1.9 (1.7–2.9) χ2(3) = 6.94, p = 0.074
Time taken to reach pVL < 50 copies/mL, 
 daysa
51.5 (7–174) 51.5 (21–188) 27.5 (6–121) 32.5 (21–63) χ2(3) = 12.99, p = 0.005
PI vs NNRTI, p = 0.63
PI vs INSTI, p = 0.09
PI vs ABC/3TC/AZT, p = 0.07
NNRTI vs INSTI, p = 0.05
NNRTI vs ABC/3TC/AZT, p = 0.35
INSTI vs ABC/3TC/AZT, p = 0.45
Women with pVL < 50 copies/mL at 
36 weeks’ gestation
95 (72.0) 21 (65.6) 13 (76.5) 11 (100) p = 0.13
Women with pVL < 50 copies/mL at 
delivery
113 (85.6) 24 (75.0) 16 (94.1) 11 (100) p = 0.17
Values are median (range) or total (%)
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24  weeks’ gestation are based on the results published 
by Read et al. [11]. However, it is important to note that 
cART regimens in this study only included PIs, NNR-
TIs and ABC/3TC/AZT and did not include INSTI-
based cART. Given the faster rate of HIV RNA declines 
in women on INSTIs as demonstrated in our study and 
other published data [26], the latest gestational age before 
which women on INSTI-based cART should have com-
menced cART will need to be explored in future studies.
Excluding ABC/3TC/AZT due to small subject num-
bers, only 66–77% of women on PIs, NNRTIs and INSTIs 
had undetectable pVL at 36  weeks’ gestation, when 
obstetric delivery plans are usually finalised. Of these 
women, those on INSTIs had the highest proportion of 
undetectable pVL by delivery and a shorter time to an 
undetectable pVL, despite starting with significantly 
higher  VLBL, mirroring the findings seen in randomised 
trials of cART initiation during pregnancy performed 
in low and middle-income countries (DolPHIN-2 study 
[27]: dolutegravir versus efavirenz-based cART and the 
National Institute of Child Health and Human Develop-
ment P1081 study [28]: raltegravir versus efavirenz-based 
cART). At present, INSTIs are considered the preferred 
antiretroviral third agent for women presenting late in 
pregnancy, yet in our study cohort, gestational age when 
cART was initiated was numerically earlier with INSTIs 
than with the other classes, reflecting the recommenda-
tion to initiate cART earlier in women with high baseline 
pVL. Over 90% of women in our study initiated cART 
before 28  weeks’ gestation but the low overall mater-
nal CD4+ counts prior to initiating cART indicates that 
many of these women were presenting late in the course 
of their HIV infection.
While the small number of women who initiated 
ABC/3TC/AZT in pregnancy all had an undetect-
able pVL at delivery, they had lower  VLBL and higher 
CD4+ counts than women who initiated PIs and NNR-
TIs, consistent with a targeted approach for initiating 
ABC/3TC/AZT. The results seen in this subgroup of 
women should therefore not be extrapolated to women 
with higher  VLBL and lower baseline CD4+ counts.
Limitations of our study include the small number of 
subject initiating INSTIs, preventing statistical analy-
sis of the clinical effects between the individual INSTI 
agents, and the long data collection period, mean-
ing that data were collected and analysed for antiret-
roviral drugs that are now rarely used or commenced 
in the UK. While the exclusion of subjects with poor 
adherence reported by either the subject or clinician 
was necessary to enable the accurate calculation of the 
first-phase HIV RNA half-life decay during treatment, 
this may have led to inadvertent subject selection bias. 
Recent modelling studies have since suggested that on 
INSTI-based cART regimens, the original first phase 
T/2 described may be replaced by a split first phase 
(phase 1a and 1b), followed by the second phase which 
starts at a lower plasma viral load than the start of the 
second phase with PI and NNRTIs [29]. We were una-
ble to explore this concept in our study.
The findings of this observational study support the 
use of INSTIs when initiating cART in pregnancy, espe-
cially in women presenting later in pregnancy and/or 
with higher  VLBL on the basis of achieving rapid reduc-
tions in pVL and an undetectable viral load at delivery. 
However, it is important to note that non-INSTI-based 
regimens also performed well. Whilst awaiting fur-
ther data on the higher incidence (0.3%) of neural tube 
defects in infants born to women conceiving on dolute-
gravir [30], there may well be a decrease in the use of 
dolutegravir, and possibly INSTIs as a whole, especially 
when initiating cART in the first trimester of preg-
nancy. In the meantime, other third agent antiretroviral 
drugs with more data on safety and efficacy in preg-
nancy that perform well in pregnancy are likely to be 
used in preference.
Conclusions
Higher baseline maternal pVL was the sole independ-
ent factor associated with faster HIV RNA decay 14 days 
after cART initiation. Lower maternal pVL 14 days after 
initiating cART, but not lower baseline maternal pVL, 
was associated with a higher chance of having an unde-
tectable maternal pVL at 36 weeks’ gestation.
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